ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2016
Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities.Frontiers in oncology · 2026Review
- Review
- CXCL10 Secreted by Pericytes Mediates TNFα-Induced Vascular Leakage in Tumors and Enhances Extravasation of Nanoparticle-Based Chemotherapeutics.Cancer research · 2025Article
- Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment.Theranostics · 2025Review
- Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice.EBioMedicine · 2024Article
- Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials.Targeted oncology · 2024Review
- Tumor microenvironment in a minipig model of spinal cord glioma.Journal of translational medicine · 2023Article
- Tumor microenvironment in a minipig model of spinal cord glioma.Journal of translational medicine · 2023Article
- The Provocative Roles of Platelets in Liver Disease and Cancer.Frontiers in oncology · 2021Review
- Alpha emitting nuclides for targeted therapy.Nuclear medicine and biology · 2021Review
- Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice.Frontiers in oncology · 2021Review
- A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles.Cancer biotherapy & radiopharmaceuticals · 2020Article
- VCAM-1 targeted alpha-particle therapy for early brain metastases.Neuro-oncology · 2020Article
- Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases.Pharmaceutics · 2019Review
- Leveraging Bioorthogonal Click Chemistry to ImproveClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.Advances in experimental medicine and biology · 2019Article
- Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.Frontiers in pharmacology · 2019Review
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.Targeted oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Tumors escape antiangiogenic therapy by activation of proangiogenic signaling pathways. Bevacizumab is approved for the treatment of recurrent glioblastoma, but patients inevitably develop resistance to this angiogenic inhibitor. We previously investigated targeted α-particle therapy with
methodsWe investigated remodeling of the tumor microenvironment in transgenic Ntva glioblastoma mice using a therapeutic 7.4-kBq dose of
resultsThe mechanism of drug action is a combination of remodeling of the glioblastoma vascular microenvironment, relief of edema, and depletion of regulatory T and endothelial progenitor cells. The primary remodeling event is the reduction of both endothelial and perivascular cell populations. Tumor-associated edema and necrosis were lessened, resulting in increased perfusion and reduced diffusion. Pharmacologic uptake of dasatinib into tumor was enhanced after α-particle therapy.
conclusionTargeted antivascular α-particle radiation remodels the glioblastoma vascular microenvironment via a multimodal mechanism of action and provides insight into the vascular architecture of platelet-derived growth factor-driven glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.